Translational Stroke Research: From Target Selection to Clinical Trials is part of "Springer Series in Translational Stroke Research." Forty-three chapters from leading stroke research groups around the world select future targets and methods for stroke management such as the vasculature and white matter, protein aggregation, neuroglobin, microRNAs, oxidation, soluble epoxide hydrolase, apoptosis, hypoxia-inducible factors, thrombin, toll- like receptor, angiogenesis, membrane potentials and pumps. The book discusses methods to regulate brain temperature and the use of preconditioning in stroke. It also presents new areas of research emphasizing restoration of function with growth factors and stem cells. It provides multiple animal models of both ischemic and hemorrhagic stroke in order to translate basic preclinical findings to clinical trials with de-risking issues, therapy delivery methods such as sustained-release and intranasal delivery, and potential therapies including cell therapies, albumin, transcranial laser, microbubbles, and ultrasound. Finally, it debates clinical trial design for analytical methodology, imaging, computation, and innovations.

This book discusses recent advances in the field of translational stroke research. The editors have designed the book to provide new insight into the importance of regeneration and repair mechanisms for stroke victims. The editors have brought together a talented group of international stroke researchers and clinicians to contribute to this volume, which is written for students, researchers and physicians in biotechnology, neurosciences, neurology, neuroradiology and neurosurgery. Throughout the world, stroke is still a leading cause of mortality and morbidity; there are 152,000 strokes in the United Kingdom, 62,000 in Canada, and approximately 15 million people worldwide. Large communities of stroke survivors are eagerly awaiting scientific advances in translational stroke research related to regeneration and recovery of function that would offer new therapeutics for rehabilitation and regeneration utilizing novel stem cell and molecular-based approaches. This volume will allow the reader to undersnd the future of stroke treatment from its inception in the laboratory through to clinical trial design. The reader will learn about the recent advances made in these areas related to basic and applied stroke research and their translational potential. Dr. Paul A. Lapchak is Professor of Neurology and Director of Translational Research in the Departments of Neurology & Neurosurgery at Cedars-Sinai Medical Center in Los Angeles CA, USA. Dr. Lapchak is an internationally recognized expert conducting translational drug development research for ischemic and hemorrhagic stroke. Dr. John H. Zhang is Professor of Anesthesiology, Neurosurgery, Neurology, and Physiology, and Director, Center for Neuroscience Research at Loma Linda University School of Medicine, Loma Linda, CA, USA. Dr. Zhang is an internationally recognized expert working on drug development for hemorrhagic stroke.

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.